Terms: = Leukemia AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb AND Treatment
118 results:
1. Enhancer looping protein LDB1 modulates myb expression in T-ALL cell lines in vitro by cooperating with master transcription factors.
Li Y; Zhang Z; Yu J; Yin H; Chu X; Cao H; Tao Y; Zhang Y; Li Z; Wu S; Hu Y; Zhu F; Gao J; Wang X; Zhou B; Jiao W; Wu Y; Yang Y; Chen Y; Zhuo R; Yang Y; Zhang F; Shi L; Hu Y; Pan J; Hu S
J Exp Clin Cancer Res; 2024 Oct; 43(1):283. PubMed ID: 39385230
[TBL] [Abstract] [Full Text] [Related]
2. hnRNPA0 promotes myb expression by interacting with enhancer lncRNA MY34UE-AS in human leukemia cells.
Liu C; Wang Y; Shi M; Tao X; Man D; Zhang J; Han B
Biochem Biophys Res Commun; 2024 Sep; 724():150221. PubMed ID: 38865811
[TBL] [Abstract] [Full Text] [Related]
3. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic leukemia.
Cruz-Miranda GM; Olarte-Carrillo I; Bárcenas-López DA; Martínez-Tovar A; Ramírez-Bello J; Ramos-Peñafiel CO; García-Laguna AI; Cerón-Maldonado R; May-Hau D; Jiménez-Morales S
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339034
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
5. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
7. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of single-cell sequencing results of an elderly patient with myeloid leukemia reveals high expression of multiple oncogenes in monocytes and hematopoietic stem cells.
Xu X; Xiong M; Ye H; Qi Y; Zhao Y
Hematology; 2023 Dec; 28(1):2240129. PubMed ID: 37535066
[TBL] [Abstract] [Full Text] [Related]
9. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
[TBL] [Abstract] [Full Text] [Related]
10. Harnessing the myb-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract] [Full Text] [Related]
11. Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.
Bašová P; Paszeková H; Minařík L; Dluhošová M; Burda P; Stopka T
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743167
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
[TBL] [Abstract] [Full Text] [Related]
13. Src-Family Protein Kinase Inhibitors Suppress myb Activity in a p300-Dependent Manner.
Biyanee A; Yusenko MV; Klempnauer KH
Cells; 2022 Mar; 11(7):. PubMed ID: 35406726
[TBL] [Abstract] [Full Text] [Related]
14. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
15. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
[TBL] [Abstract] [Full Text] [Related]
16. Hsa-circ_0003420 induces apoptosis in acute myeloid leukemia stem cells and impairs stem cell properties.
Lin G; Fei Y; Zhang Y
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):622-631. PubMed ID: 34477035
[TBL] [Abstract] [Full Text] [Related]
17. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract] [Full Text] [Related]
18. C/EBPβ is a myb- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.
Yusenko MV; Trentmann A; Casolari DA; Abdel Ghani L; Lenz M; Horn M; Dörner W; Klempnauer S; Mootz HD; Arteaga MF; Mikesch JH; D'Andrea RJ; Gonda TJ; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Oncogene; 2021 Jul; 40(29):4746-4758. PubMed ID: 33958723
[TBL] [Abstract] [Full Text] [Related]
19. [Effect of MiR-96 on Cell Invasion and Apoptosis in Pediatric Acute Myeloid leukemia via Regulating myb].
Wang XL; Wang WF; Hao JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):439-444. PubMed ID: 33812412
[TBL] [Abstract] [Full Text] [Related]
20. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
Silva LR; da Silva-Júnior EF
Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
[TBL] [Abstract] [Full Text] [Related]
[Next]